The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price target ...

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...